Royal Bank of Canada’s Innovator IBD ETF Leaders ETF LDRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-1,000
Closed -$24K 7442
2020
Q3
$24K Hold
1,000
﹤0.01% 5633
2020
Q2
$20K Hold
1,000
﹤0.01% 5601
2020
Q1
$19K Buy
1,000
+350
+54% +$7.49K ﹤0.01% 5581
2019
Q4
$15K Buy
650
+150
+30% +$3.33K ﹤0.01% 6002
2019
Q3
$11K Buy
500
+330
+194% +$7.22K ﹤0.01% 5759
2019
Q2
$4K Hold
170
﹤0.01% 6436
2019
Q1
$4K Hold
170
﹤0.01% 6380
2018
Q4
$4K Sell
170
-330
-66% -$7.54K ﹤0.01% 6280
2018
Q3
$12K Hold
500
﹤0.01% 5921
2018
Q2
$12K Sell
500
-22,055
-98% -$545K ﹤0.01% 5773
2018
Q1
$555K Buy
22,555
+22,280
+8,102% +$572K ﹤0.01% 3629
2017
Q4
$7K Buy
+275
New +$6.98K ﹤0.01% 6008

Other funds holding LDRS

Royal Bank of Canada's LDRS Position: Q4 2020 in Review

Royal Bank of Canada sold out of Innovator IBD ETF Leaders ETF (LDRS) in Q4 2020, closing a stake of 1,000 shares — an estimated $24K sold.

Royal Bank of Canada first reported a position in LDRS in Q4 2017 and held it in 12 quarters. The position peaked at $555K in Q1 2018. 4 funds tracked by Wall St. Rank hold LDRS as of Q4 2020.

  • Royal Bank of Canada reported no remaining Innovator IBD ETF Leaders ETF position as of Q4 2020 after selling out during the quarter.
  • Royal Bank of Canada sold 1,000 Innovator IBD ETF Leaders ETF shares in Q4 2020, an estimated $24K.
  • Royal Bank of Canada first reported a position in Innovator IBD ETF Leaders ETF in Q4 2017 and held it in 12 quarters.
  • Royal Bank of Canada's Innovator IBD ETF Leaders ETF position peaked at $555K in Q1 2018.
  • 4 funds tracked by Wall St. Rank held Innovator IBD ETF Leaders ETF as of Q4 2020.

Based on Royal Bank of Canada's 13F filing for Q4 2020, filed 16 Feb 2021.